NanoVation Therapeutics
NanoVation Therapeutics is a Vancouver-based private biotechnology company that develops proprietary long-circulating lipid nanoparticle (lcLNP™) technology for nucleic acid delivery beyond the liver. It serves pharmaceutical and biotechnology partners through collaborative co-development, licensing, and milestone-based agreements.
- Company typePrivate
- Founded2019
- HeadquartersVancouver, Canada
- Headcount11–50
- GTM typeB2B
- OfferingServices
What NanoVation Therapeutics does
NanoVation Therapeutics is a private Canadian biotechnology company headquartered in Vancouver, BC, founded in 2019 by a multi-institutional team of LNP scientists from the University of British Columbia, the Medical College of Wisconsin, and other institutions. The company develops next-generation lipid nanoparticle (LNP) delivery technologies designed to overcome the principal bottleneck in genetic medicine: safe and efficient delivery of nucleic acids to tissues beyond the liver. Its flagship long-circulating LNP (lcLNP™) platform demonstrates up to 18-hour circulation half-life in non-human primates (versus less than one hour for conventional LNPs) and has shown functional delivery to bone marrow, solid tumors, immune compartments, and skin.
The technology stack is anchored by the proprietary lcLNP platform and the broader NTx Toolbox, a one-stop-shop intellectual property portfolio that spans novel ionizable lipid libraries synthesized via low-cost bucket chemistry, proprietary mRNA modifications and caps, LNP compositions, and surface modifications including PEGless formulations. Supporting infrastructure includes the GENErator™ encapsulation facility in Harwell, UK, and a European office in Berlin, complementing the UBC-campus headquarters. Named scientific leadership includes Pieter Cullis (Board Chair), Dominik Witzigmann (President), and Jayesh Kulkarni (CSO), supported by advisors and board members with track records at companies that delivered Onpattro and Comirnaty.
NanoVation operates a B2B platform business model, monetizing through collaborative co-development arrangements, licensing, milestone payments, and tiered royalties with pharmaceutical and biotechnology partners. Customers to date include Novo Nordisk (multi-target genetic medicine partnership with up to US$600 million in upfront and milestone potential), Baseimmune (preclinical mRNA vaccines), and ME Therapeutics (myeloid-cell cancer therapeutics). The company also benefits from non-dilutive government grant funding through programs such as Innovate BC's Ignite award.
NanoVation Therapeutics firmographics
Firmographics- Name
- NanoVation Therapeutics
- Legal name
- NanoVation Therapeutics Inc.
- Website
- https://nanovationtx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NanoVation Therapeutics is a Vancouver-based private biotechnology company that develops proprietary long-circulating lipid nanoparticle (lcLNP™) technology for nucleic acid delivery beyond the liver. It serves pharmaceutical and biotechnology partners through collaborative co-development, licensing, and milestone-based agreements.
- Ownership category
- akta.pro rank
NanoVation Therapeutics industry classification
Industry- Product category
- Drug Delivery Technology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)
Keywords
Where NanoVation Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
NanoVation Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Partnership and Licensing Revenue: Research funding and milestone payments from pharmaceutical partners. Eligibility for up to US$600 million in upfront cash and potential milestone payments plus tiered royalties on future product sales from Novo Nordisk partnership. Multi-year collaborative arrangements with upfront payments, development milestones, and commercial royalties.
- Government Grants: Innovation BC Ignite program funding awards for research and development projects, such as the $300,000 award for mRNA stability and production enhancement.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
NanoVation Therapeutics product offering
Product offeringCore offering
NanoVation Therapeutics develops and provides lipid nanoparticle (LNP) delivery technologies for nucleic acid-based therapeutics. Its flagship offering is the long-circulating LNP (lcLNP) platform, which enables functional delivery of mRNA, siRNA, DNA, and gene editing constructs to tissues beyond the liver (bone marrow, tumors, immune compartments, skin). The company offers customized LNP design and a co-development partnership model for pharmaceutical and biotechnology clients developing genetic medicines.
Product overview
NanoVation Therapeutics is a platform company developing next-generation lipid nanoparticle (LNP) technologies for nucleic acid delivery. The company's core offering consists of its proprietary long-circulating LNP (lcLNP™) platform as the flagship technology, complemented by the NTx Toolbox which provides a comprehensive IP portfolio covering ionizable lipid libraries, LNP compositions, surface modifications, and mRNA modifications. The platform enables customized delivery solutions for various tissues (beyond the liver), payloads (mRNA, siRNA, DNA, gene editing constructs), and administration routes. The company also offers HepLNP for liver-targeted delivery and operates the GENErator™ facility for partner programs.
Differentiator
Problem solved
Functional benefit
Products and services
- lcLNP™ (Long-Circulating LNP) Platform
Quantifiable outcome
- Up to 18h circulation half-life in NHP (vs <1h for conventional LNPs)
- +2 more outcomes
Companies that use NanoVation Therapeutics
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
NanoVation Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
NanoVation Therapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and secondary.
- Novo NordiskcoreMulti-year partnership to develop genetic medicines targeting cardiometabolic and rare diseases. NanoVation will receive research funding and is eligible to receive up to approximately US$600 million in upfront cash and potential milestone payments, plus tiered royalties on future product sales. Partnership focuses on two lead programs for base-editing therapies targeting rare genetic diseases and up to five additional future targets, utilizing NanoVation's lcLNP technology for extrahepatic delivery.
- BaseimmunecorePreclinical partnership program to develop more effective vaccines against COVID, malaria, and African swine fever. Baseimmune creates informatics-empowered universal antigens and NanoVation provides customized LNP formulations for mRNA delivery. Testing conducted in preclinical models by Baseimmune. Baseimmune in London will create antigen-encoded mRNA and NanoVation's GENErator facility in Harwell, UK will encapsulate mRNA in tailor-made LNPs.
- ME TherapeuticssecondaryPartnership to target myeloid cells with precision for cancer therapeutics using NanoVation's lcLNP platform. ME Therapeutics describes the collaboration as transformative for entering the field of therapeutic mRNA development.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
NanoVation Therapeutics competitors and assessment
Company assessmentDirect peers
- Acuitas Therapeutics: Vancouver-based LNP delivery technology company that developed the LNP system for Pfizer-BioNTech's Comirnaty COVID-19 vaccine. Direct competitor to NanoVation in ionizable lipid LNP technology for nucleic acid delivery, with established enterprise pharma partnerships.
- Genevant Sciences: LNP and ligand-based delivery platform for RNA therapeutics with multiple pharma partnerships. Competes directly with NanoVation in developing next-generation LNPs for nucleic acid payloads, particularly for extrahepatic delivery.
Emerging players
- Replicate Bioscience: Clinical-stage RNA therapeutics company with proprietary self-replicating RNA platform. Comparable as an emerging player developing novel RNA delivery approaches for cancer and infectious disease applications.
- Strand Therapeutics: Developer of mRNA therapeutics with programmable, self-replicating RNA technology for cancer and other diseases. Comparable as an emerging genetic medicines company working on novel delivery and RNA design for extrahepatic indications.
- Etherna Immunotherapies: Belgium-based developer of mRNA immunotherapies using proprietary LNP and lipopolyplex delivery technologies. Comparable in combining novel delivery technology with therapeutic partnerships, though more vertically integrated than NanoVation.
Broad incumbents
- Arcturus Therapeutics: Clinical-stage mRNA medicines company with proprietary LNP delivery technology and self-amplifying RNA platforms. Comparable in its focus on combining novel nucleic acid payloads with custom LNPs, though it owns clinical assets rather than partnering only at the platform level.
- BioNTech: Global mRNA therapeutics leader with extensive internal LNP and lipid chemistry capabilities acquired through its University of Pennsylvania and Acuitas-adjacent work. Comparable in target market (pharma/biotech needing LNP delivery) but operates at vastly larger scale with internal pipeline.
- CureVac: Clinical-stage mRNA therapeutics company with proprietary lipid carriers and RNA optimization technology. Comparable as a developer of novel LNPs and mRNA modifications for therapeutic applications, though it operates its own clinical pipeline.
- Moderna: Commercial-stage mRNA company with proprietary LNP delivery technology used in approved COVID-19 and RSV vaccines. Competes in the broader nucleic acid delivery market and has internal R&D programs targeting extrahepatic delivery.
- Precision NanoSystems (Cytiva): Provides LNP formulation technologies, microfluidic manufacturing equipment, and CDMO services for nanomedicine development. Comparable as a one-stop LNP platform and services provider for pharma and biotech partners developing nucleic acid therapeutics.
Market position
Strengths4 records
Weaknesses4 records
Key risks5 records
Key highlights6 records
Customer concentration
NanoVation Therapeutics social profiles
Digital presenceNanoVation Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
NanoVation Therapeutics leadership team
Management profileNumber of profiles
Profiles16 records
NanoVation Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NanoVation Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NanoVation Therapeutics
What does NanoVation Therapeutics do?
NanoVation Therapeutics develops and provides lipid nanoparticle (LNP) delivery technologies for nucleic acid-based therapeutics. Its flagship offering is the long-circulating LNP (lcLNP) platform, which enables functional delivery of mRNA, siRNA, DNA, and gene editing constructs to tissues beyond the liver (bone marrow, tumors, immune compartments, skin). The company offers customized LNP design and a co-development partnership model for pharmaceutical and biotechnology clients developing genetic medicines.
Is NanoVation Therapeutics a public or private company?
NanoVation Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was NanoVation Therapeutics founded?
NanoVation Therapeutics was founded in 2019. It employs 11 to 50 people.
Where is NanoVation Therapeutics based?
NanoVation Therapeutics is headquartered in Vancouver, Canada, in the North America region.
How does NanoVation Therapeutics make money?
Two revenue lines are on record. Partnership and Licensing Revenue is the primary driver. The others are government Grants.
Who are NanoVation Therapeutics's main competitors?
Direct peers on record are Acuitas Therapeutics and Genevant Sciences. Emerging players are Replicate Bioscience, Strand Therapeutics and Etherna Immunotherapies. Broad incumbents are Arcturus Therapeutics, BioNTech, CureVac, Moderna and Precision NanoSystems (Cytiva).
Does NanoVation Therapeutics have an API?
No public API is recorded for NanoVation Therapeutics.
What industry is NanoVation Therapeutics in?
NanoVation Therapeutics's product category is Drug Delivery Technology. Its primary akta.pro industry code is HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes). Its NAICS code is 541714 and its SIC code is 8731.